Flex Pharma (NASDAQ:FLKS) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Thursday, March 15th.
A number of other analysts have also recently commented on the stock. Ladenburg Thalmann initiated coverage on shares of Flex Pharma in a report on Thursday, January 25th. They set a “buy” rating and a $12.00 target price on the stock. Roth Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of Flex Pharma in a research report on Wednesday, January 3rd. Zacks Investment Research raised shares of Flex Pharma from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Friday, December 1st. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $6.00 price target on shares of Flex Pharma in a research report on Wednesday, March 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $8.55.
FLKS traded down $0.40 on Thursday, reaching $4.98. The company had a trading volume of 75,420 shares, compared to its average volume of 148,947. Flex Pharma has a 52-week low of $2.68 and a 52-week high of $8.98.
Flex Pharma (NASDAQ:FLKS) last posted its quarterly earnings results on Wednesday, March 7th. The biotechnology company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.10. Flex Pharma had a negative net margin of 2,698.59% and a negative return on equity of 85.02%. The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.36 million. analysts anticipate that Flex Pharma will post -1.88 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Granite Point Capital Management L.P. grew its position in shares of Flex Pharma by 80.8% during the 4th quarter. Granite Point Capital Management L.P. now owns 71,520 shares of the biotechnology company’s stock worth $250,000 after buying an additional 31,961 shares in the last quarter. Renaissance Technologies LLC boosted its position in Flex Pharma by 67.1% during the fourth quarter. Renaissance Technologies LLC now owns 89,900 shares of the biotechnology company’s stock valued at $314,000 after purchasing an additional 36,100 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Flex Pharma by 10.0% during the third quarter. Ameriprise Financial Inc. now owns 720,524 shares of the biotechnology company’s stock valued at $2,457,000 after purchasing an additional 65,699 shares in the last quarter. Finally, Sphera Funds Management LTD. raised its stake in shares of Flex Pharma by 70.7% in the fourth quarter. Sphera Funds Management LTD. now owns 241,211 shares of the biotechnology company’s stock worth $4,339,000 after purchasing an additional 99,911 shares during the last quarter. 28.96% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Flex Pharma (FLKS) Upgraded to “Sell” by ValuEngine” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/08/flex-pharma-flks-rating-increased-to-sell-at-valuengine.html.
About Flex Pharma
Flex Pharma, Inc, a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company operates through two segments, Consumer Operations and Drug Development.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.